TY  - JOUR
T1  - Formulation and Evaluation of Dolutegravir Sodium Nanoemulsion for the Treatment of HIV
A1  - Paul Bastyav Rodriques
A1  - Bhupendra Gopalbhai Prajapati
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2022
VL  - 13
IS  - 6
DO  - 10.51847/gnVuQuUCIf
SP  - 1
EP  - 8
N2  - The purpose of this research was to develop and evaluate the Nanoemulsion of Dolutegravir sodium. Nanoemulsion was made by the high-shear homogenization method. Materials and method: Oleic acid was used as the oil phase, Tween 80, and Acconon MC8-2 EP/NF (Smix; 1:1) were utilized as surfactant and co-surfactant respectively while distilled water was employed as an aqueous phase. The formulations were evaluated based on globule size, zeta potential, pH, viscosity, percentage transmittance, centrifugation, dye test, dilutability test, and Fourier transform spectroscopy. Furthermore, in vitro drug release studies and stability studies were also conducted. NE1 has shown the least particle size of 96.71 nm, viscosity of 86.4 cp, and maximum drug release of 97.55 % CDR in 45 hrs compared with pure drug (32.98% CDR in 45 hrs). The stability study confirmed no changes in formulations at 1 month at 400 ± 20C and 75% ± 5%. The findings suggest that nanoemulsions might be an effective vehicle for the oral administration of Dolutegravir sodium for the treatment of HIV.
UR  - https://pharmacophorejournal.com/article/formulation-and-evaluation-of-dolutegravir-sodium-nanoemulsion-for-the-treatment-of-hiv-38sh5g01f1b5n6b
ER  -